Effects of various tricyclic antidepressants on amine uptake

Ito, Koichi; Shibanoki, Shinji; Kubo, Toshio; Watabe, Shigeo; Matsumoto, Akira; Kogure, Miki

doi:10.1016/0014-2999(86)90640-0

Cited by 10 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a discordant result was obtained: dothiepin, the tricyclic antidepressant most widely used in the UK, showed no increased risk (ORΩ1.0, 0.6-1.6). We advanced the explanation that in some experimental models dothiepin has shown a considerable selectivity on norepinephrine reuptake (Ishikawa et al 1986). However, as far as we know, no in vivo studies have been published on the effect of dothiepin on platelet serotonin content at therapeutic doses.…”

Section: The Epidemiological Evidencementioning

confidence: 67%

Antidepressants and Risk of Upper Gastrointestinal Bleeding

Abajo

Montero

Rodrı́guez

et al. 2006

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

Section: The Epidemiological Evidencementioning

confidence: 67%

Antidepressants and Risk of Upper Gastrointestinal Bleeding

Abajo

Montero

Rodrı́guez

et al. 2006

Basic Clin Pharma Tox

View full text Add to dashboard Cite

show abstract

“…Dothiepin, a TCA and a thio-analogue of amitriptyline (Rydzynski 1966), has been shown to have potent antidepressant and anxiolytic properties with minimal side effects (Lipsedge et al 1971;Johnson et al 1973;Lambourn and Rees 1974). Its antidepressant activity is mediated through facilitation of noradrenergic neurotransmission by uptake inhibition (Ishikawa et al 1986) and possibly also by enhancement of serotoninergic neurotransmission (Lancaster and Gonzalez 1989). The anticholinergic actions of TCAs such as dry mouth, constipation, dizziness, tachycardia and palpitation are less pronounced with dothiepin than imipramine and amitriptyline (Lambourn and Rees 1974;Sim et al 1975).…”

Section: Dothiepin (Dosulepin)mentioning

confidence: 99%

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Eap

Gründer

Baumann

et al. 2021

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

Objectives: More than 40 drugs are available to treat affective disorders. Individual selection of the optimal drug and dose is required to attain the highest possible efficacy and acceptable tolerability for every patient. Methods: This review, which includes more than 500 articles selected by 30 experts, combines relevant knowledge on studies investigating the pharmacokinetics, pharmacodynamics and pharmacogenetics of 33 antidepressant drugs and of 4 drugs approved for augmentation in cases of insufficient response to antidepressant monotherapy. Such studies typically measure drug concentrations in blood (i.e. therapeutic drug monitoring) and genotype relevant genetic polymorphisms of enzymes, transporters or receptors involved in drug metabolism or mechanism of action. Imaging studies, primarily positron emission tomography that relates drug concentrations in blood and radioligand binding, are considered to quantify target structure occupancy by the antidepressant drugs in vivo. Results: Evidence is given that in vivo imaging, therapeutic drug monitoring and genotyping and/or phenotyping of drug metabolising enzymes should be an integral part in the development of any new antidepressant drug. Conclusions: To guide antidepressant drug therapy in everyday practice, there are multiple indications such as uncertain adherence, polypharmacy, nonresponse and/or adverse reactions under therapeutically recommended doses, where therapeutic drug monitoring and cytochrome P450 genotyping and/or phenotyping should be applied as valid tools of precision medicine.

show abstract

“…Among them were compounds whose acute biochemical effeet is preferential or seleetive reuptake inhibition of noradrenalin (desipramine, amoxapine, dibenzepine, maprotiline), of serotonin (c1omipramine, fluvoxamine, trazo-Treatment q(Depressions Resistant to Tricye/ic Antidepressants Pharmacopsychiat. 22 (1989) 2ZZ.. done, zimelidine), or of both transmitters without preference (amitriptyline, dothiepin, doxepin, imipramine, nortriptyline), or which have no action on reuptake (adinazolam, alprazolam, bupropion, iprindole, mianserin, trimipramine) (Waldmeier, 1983;Ishikawa et al, 1986;Hauser et al, 1985;de Montigny, 1982;Dawson etal., 1984;Lahti et al, 1982). All substances so far tested were shown to be associated with efficacious lithium addition.…”

Section: Variables Related To Outcomementioning

confidence: 99%

Treatment of Depressions Resistant to Tricyclic Antidepressants, Related Drugs or MAO-Inhibitors by Lithium Addition: Review of the Literature

Schöpf¹

1989

Pharmacopsychiatry

View full text Add to dashboard Cite

Although it might be premature to consider the efficacy of lithium addition in patients unresponsive to conventional antidepressant drug treatment as established, the evidence is suggestive. Besides 26 open studies, four out of six controlled investigations reported a positive effect of combined therapy administered in the indicated sequence. Three controlled studies confirmed the original observation of de Montigny et al. that improvement may occur within 48 hours. Successful lithium addition was reported in different types of depression and after pretreatment with tricyclic antidepressants, related compounds or MAO-inhibitors. Preliminary recommendations with respect to the practical use of lithium addition are made.

show abstract

Effects of various tricyclic antidepressants on amine uptake

Cited by 10 publications

References 10 publications

Antidepressants and Risk of Upper Gastrointestinal Bleeding

Antidepressants and Risk of Upper Gastrointestinal Bleeding

Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants

Treatment of Depressions Resistant to Tricyclic Antidepressants, Related Drugs or MAO-Inhibitors by Lithium Addition: Review of the Literature

Contact Info

Product

Resources

About